The manuscript posted on bioRxiv frames Small intestine neuroendocrine tumors (SI-NETs) as clinically challenging due to a high metastatic rate and the scarcity of effective systemic therapies. The title indicates the study connects RNA splicing alterations with differences in patient survival, but the supplied excerpt of the preprint does not include the experimental results or detailed analyses that would substantiate that link.
Investigators reported a multidisciplinary author list with affiliations spanning translational cell biology and multiple clinical oncology departments in Spain. Key affiliations named in the source include the University of Córdoba and several departments at Vall d'Hebron University Hospital, along with other Spanish oncology centers. Correspondence is directed to justo@uco.es. The posting is explicitly an unrefereed preprint on bioRxiv with DOI https://doi.org/10.64898/2026.10.22.760955, which the authors and readers should treat accordingly.
The available abstract opening reiterates the clinical problem: advanced SI-NETs carry substantial metastatic risk and limited therapeutic options. That sets the study rationale. Beyond that framing, the supplied content stops; the source did not report specific experimental findings, statistical outcomes, or described mechanistic pathways in the excerpt provided. The manuscript title suggests a focus on splicing as a molecular basis for prognostic heterogeneity, but the text necessary to evaluate that claim—data, analyses, and quantified results—is not present in the supplied source.
The bioRxiv entry listed multiple supporting links: a preview PDF, a supplementary materials file, and tabs for abstract, info/history, and metrics on the article page. The source indicated those materials exist, but the excerpt did not include their content. Readers interested in methods or data should consult the full article page or supplementary material on bioRxiv for the complete dataset and analytical details.
The supplied preprint excerpt did not report core methodological elements that are necessary to interpret any molecular claims. The source did not provide the following in the available text: sample size or cohort selection criteria; tumor staging or grading used to define “advanced” disease; sequencing platform(s) or read depth for splicing analysis; bioinformatic pipelines or statistical models; survival endpoints (overall survival, progression-free survival, or other); adjustment covariates in survival models; or any specific genes, splicing events, or signatures implicated. The absence of those elements in the supplied excerpt prevents assessment of analytical rigor and reproducibility.
The study’s title raises several clinically relevant questions that the supplied source did not answer. Clinicians will want to know whether any identified splicing alterations (if reported in the full preprint) are independently prognostic after controlling for standard clinical factors; whether alterations map to druggable pathways; if the authors propose a clinically deployable biomarker assay; and whether the findings were validated in independent cohorts. The supplied excerpt does not report on validation, assay development, or any claims about clinical utility.
The source excerpt contains explicit limits of disclosure: it is a preprint and has not been certified by peer review, which the authors and bioRxiv clearly state. The provided text did not supply empirical results or downstream validation, and therefore the following are concrete limitations based on the supplied content: absence of reported datasets and analytical details in the excerpt; no reported survival analyses or effect sizes in the supplied material; and no methodological transparency within the excerpt to permit independent evaluation. The supplied content did not state any regulatory milestones or next steps toward clinical translation.
Because the available source text is incomplete, readers should consult the full preprint page (including the preview PDF and supplementary material linked on bioRxiv) to access the methods, results, and any proposed translational recommendations. Until those elements have been reviewed and replicated in peer-reviewed venues, any mechanistic or prognostic claims about splicing in SI-NETs remain provisional.